Skip to content

Evaluating the effect of doxycycline in patients with respiratory infection caused by colistin-resistant Klebsiella

The Role of Doxycycline in the Therapy of Colistin Resistant Klebsiella Pneumoniae

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200325046854N4
Enrollment
30
Registered
2024-08-24
Start date
2024-08-27
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colistin Resistant Klebsiella Pneumoniae. Pneumonia due to Klebsiella pneumoniae

Interventions

Intervention 1: Intervention group: Doxycycline + Standard Treatment + Colistin: the medication regimen of this group will be doxycycline 100 capsules twice a day along with Colistin 2.5-5 mg/kg BD an

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Positive culture response to Klebsiella Pneumoniae and its resistance to Colistin Age 18 or above Insensitivity/interference of Doxycycline with the patient's current treatment.

Exclusion criteria

Exclusion criteria: Negative culture response to Klebsiella and subsidence of clinical symptoms Causing severe side effects in the patient during treatment Lack of consent of the patient or their companions to participate or continue the study

Design outcomes

Primary

MeasureTime frame
Evaluating patient's clinical symptoms, especially fever. Timepoint: daily. Method of measurement: vital signs monitor.

Secondary

MeasureTime frame
Mortality rate. Timepoint: daily. Method of measurement: Loss of vital signs and death of the patient.;Investigating the possibility of recurrent infections. Timepoint: one week after the intervention. Method of measurement: blood culture.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShaghayegh Abaft

Islamic Azad University

Shaghayeghabaft19@gmail.com+98 21 2264 0051

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026